Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Nektar Therapeutics advances rezpegaldesleukin into the Phase 3 ZENITH-AD programme, testing whether Treg stimulation can transform atopic dermatitis treatment. Representative image.
Pharma & Biotech

Nektar Therapeutics starts Phase 3 ZENITH-AD trials of rezpegaldesleukin for atopic dermatitis

Nektar Therapeutics has initiated the first two studies in a 1,530-patient Phase 3 programme evaluating rezpegaldesleukin in adolescents and adults with moderate-to-severe atopic dermatitis, beginning the pivotal test of whether regulatory T-cell stimulation can compete with established eczema biologics and oral medicines. ZENITH AD-1 and ZENITH AD-2 will each enroll approximately 510 patients who have

Read More
Laboratory research into sickle cell disease therapies highlights Agios Pharmaceuticals’ decision to halt tebapivat development after mixed Phase 2 results, shifting investor focus to mitapivat. Representative image.
Pharma & Biotech

Agios Pharmaceuticals stops tebapivat sickle cell development after mixed Phase 2 results

Agios Pharmaceuticals, Inc. has decided not to advance tebapivat in sickle cell disease after a randomized Phase 2 trial involving 59 participants failed to establish the differentiated clinical profile required for further investment. The Nasdaq-listed rare-disease drug developer said the once-daily pyruvate kinase activator improved haemoglobin and markers of haemolysis, but the response pattern did

Read More
Representative image of a modern surgical operating room, reflecting PolyPid’s D-PLEX100 partnership with Azurity Pharmaceuticals and the potential role of local antibiotic delivery in preventing surgical site infections after abdominal colorectal surgery.
Pharma & Biotech

PolyPid signs Azurity partnership for D-PLEX100 commercialization in the U.S. and Canada

PolyPid’s Azurity partnership gives D-PLEX100 a U.S. and Canada launch path after Phase 3 SHIELD II surgical site infection data

Read More
European Commission approval of Kyowa Kirin’s Crysvita expands X-linked hypophosphataemia treatment to infants from one month of age across the European Union. Representative image.
Pharma & Biotech

Kyowa Kirin wins European Crysvita approval for infants from one month of age

Crysvita wins European Union approval for infants from one month, widening early XLH treatment and strengthening Kyowa Kirin’s rare disease franchise.

Read More
Aptar Beauty achieves first commercial launch of NeoDropper Autoload technology
Pharma & Biotech

Aptar Beauty’s Dermalogica debut puts its automatic skincare dropper to the real market test

Aptar Beauty’s NeoDropper Autoload debuts with Dermalogica, testing precision dosing, formula protection and premium skincare adoption.

Read More
Paediatric atopic dermatitis assessment as Almirall’s Ebglyss label-expansion filing enters European Medicines Agency review. Representative image.
Pharma & Biotech

Could Ebglyss challenge Dupixent in younger children? Almirall clears a crucial EMA filing hurdle

Almirall’s Ebglyss paediatric filing enters EMA review, opening a potential path into Europe’s childhood atopic dermatitis market.

Read More
Innate Pharma’s IPH4502 Phase 1 dose-escalation milestone advances its Nectin-4 exatecan ADC toward a 76-patient year-end readout in advanced solid tumors. Representative image.
Pharma & Biotech

Why Innate Pharma’s 76-patient IPH4502 milestone is only half the Nectin-4 story

Innate Pharma completed IPH4502 dose-escalation enrollment, putting safety, response durability and dose selection at the center of a year-end readout.

Read More
Incyte’s ESMO 2026 oncology programme will spotlight investigational treatments targeting pancreatic, colorectal and ovarian cancers. Representative image.
Pharma & Biotech

Why Incyte’s ESMO 2026 oncology readouts matter for its expanding Phase 3 pipeline

Incyte’s ESMO 2026 programme puts three investigational cancer assets under scrutiny across pancreatic, colorectal and ovarian tumours.

Read More
Bristol Myers Squibb is expanding AI drug discovery with NVIDIA Vera Rubin-powered computing infrastructure to support faster, higher-confidence research decisions. Representative image.
Pharma & Biotech

Bristol Myers Squibb is building a vast NVIDIA AI factory, but can it improve drug discovery odds?

Bristol Myers Squibb is scaling NVIDIA-powered drug discovery. Can more computing power deliver faster, higher-confidence pipeline decisions?

Read More
Galderma expands Alastin professional skincare across Japan and key Asia Pacific medical aesthetics markets as demand for procedure-linked skincare grows. Representative image.
Pharma & Biotech

Galderma is taking Alastin deeper into Asia, but this launch is about more than skincare

Galderma expands Alastin across Japan and Asia Pacific, linking premium skincare with rising demand for aesthetic procedures.

Read More